Vaccines Are Helping Older People More Than We Knew
Many shots seem to have “off-target” benefits, such as lowering the risk of dementia, studies have found.
New analysis indicates that vaccines greatly reduce hospitalisations for flu and COVID-19
A new modelling study from RespiCompass, the ECDC Respiratory Diseases Scenario Modelling Hub, indicates that influenza and COVID-19 vaccination programmes markedly reduced hospitalisations among older adults across Europe in the 2024/25 season.
Pre-existing and early cellular immune factors correlate with functionally complete protection against primary controlled human SARS-CoV-2 infection
Identifying host factors that mediate protection against newly-emergent viruses is needed for improved pandemic preparedness.
Association between vaccinations and risk of dementia: a systematic review and meta-analysis
Dementia is a highly prevalent issue in older people. Whilst the prevention of dementia is a public health priority, the role of vaccinations is still largely unexplored.
“Supporting our systems: Addressing immunosenescence and improving adult immunisation in Europe”
The International Longevity Centre UK (ILCUK) report highlights how Europe's aging population faces increasing health challenges due to immunosenescence, which reduces vaccine effectiveness and increases vulnerability to disease.
Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis
Two large-scale trials comparing high-dose inactivated influenza vaccine (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) against hospitalisation outcomes have been conducted in Denmark and Spain.
High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults
High-dose inactivated influenza vaccine has been shown to provide protection against influenza that is superior to that with the standard dose.
WHO EPI-WIN Webinar: Respiratory Syncytial Virus (RSV) genomic surveillance – how & why
Each year, RSV causes an estimated 3.6 million RSV-associated hospitalisations and approximately 100.000 RSV-attributable deaths in children under 5 years of age worldwide .